PD‐L1/TIGIT bispecific antibody showed survival advantage in animal model

Mu, Songlin; Liang, Zhijuan; Wang, Yongmei; Chu, Wendi; Chen, Yi‐Li; Wang, Qi; Wang, Guifeng; Wang, Chunhe

doi:10.1002/ctm2.754

Cited by 11 publications

(6 citation statements)

References 10 publications

(8 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Instead of combining two antibodies, some teams are developing bispecific PD-1/TIGIT antibodies, 46 which have shown improvement in OS in mouse model. 47 Another strategy can be to modify the backbone: SEA-TGT is a nonfucosylated antibody designed to have its effector function enhanced, which elicits better immune response than classical anti-TIGIT antibodies. 48 It will be evaluated in a phase I in patients with advanced solid tumors.…”

Section: Future Strategiesmentioning

confidence: 99%

Anti-TIGIT therapies for solid tumors: a systematic review

Rousseau¹,

Parisi²

2023

ESMO Open

View full text Add to dashboard Cite

Section: Future Strategiesmentioning

confidence: 99%

Anti-TIGIT therapies for solid tumors: a systematic review

Rousseau¹,

Parisi²

2023

ESMO Open

View full text Add to dashboard Cite

“…This encouraging result suggests that TIGIT is a potential target and can synergize with other ICIs. A novel bsAb targeting TIGIT and PD-L1 has also been reported, in which the bsAb promotes IL-2 secretion from T cells in vitro and improves the overall survival in a transgenic mouse model 58 . PVR-related immunoglobulin domain-containing (PVRIG) is another inhibitory molecule that binds to PVRL2, and its inhibitory ability is partially independent of the TIGIT/PVR/PVRL2 axis 59 .…”

Section: Targeting Dual Inhibitory Checkpointsmentioning

confidence: 99%

“…Both HLX301 and PM1022 are bsAbs that bind to TIGIT and PD-L1 58,101 . The bsAbs targeting TIGIT are all under phase I clinical trials, albeit lacking clinical efficacy results.…”

Section: Inhibitory Checkpoint × Inhibitory Checkpointmentioning

confidence: 99%

Bispecific antibodies targeting immunomodulatory checkpoints for cancer therapy

2023

View full text Add to dashboard Cite

Advances in antibody engineering have led to the generation of more innovative antibody drugs, such as bispecific antibodies (bsAbs). Following the success associated with blinatumomab, bsAbs have attracted enormous interest in the field of cancer immunotherapy. By specifically targeting two different antigens, bsAbs reduce the distance between tumor and immune cells, thereby enhancing tumor killing directly. There are several mechanisms of action upon which bsAbs have been exploited. Accumulating experience on checkpoint-based therapy has promoted the clinical transformation of bsAbs targeting immunomodulatory checkpoints. Cadonilimab (PD-1 × CTLA-4) is the first approved bsAb targeting dual inhibitory checkpoints, which confirms the feasibility of bsAbs in immunotherapy. In this review we analyzed the mechanisms by which bsAbs targeting immunomodulatory checkpoints and their emerging applications in cancer immunotherapy.

show abstract

“…Depending on the rapid development of bispecific antibody technologies, there are more and more novel bispecific antibodies targeting two immune checkpoints or one immune checkpoint and one other molecule such as TGF-b. The better anti-tumor efficacy is obtained in preclinical experiments when using bispecific antibodies instead of the mAbs and their combination (68,69). In June 2022 Cadonilimab (a bispecific antibody targeting PD-1 and CTLA-4) was approved in China to treat patients with relapsed or metastatic cervical cancer (17).…”

Section: Bispecific Antibodiesmentioning

confidence: 99%

Immunotherapy in cervical cancer: From the view of scientometric analysis and clinical trials

Xing

Yasinjan

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

BackgroundCervical cancer is the fourth most cancer and the fourth leading cause of cancer-related deaths in women worldwide. Current treatment for patients with advanced cervical cancer is limited. And in the urgent demand for novel effective therapies both as the first and the second line treatment for these patients, immunotherapy is developing fast and has made some achievements.MethodsThis study incorporated 1,255 topic-related articles and reviews from 1999 to 2022 in the Web of Science Core Collection (WoSCC). The WoS platform, Citespace, and VOS viewer provided the annual distribution of publications and citations, the analysis of researching countries and institutions, references, keywords (co-occurrence analysis, burst analysis, and timeline view analysis), and researching authors, respectively. For clinical trials, 720 trials and 114 trials from ClinicalTrials.gov and ICTRP were retrieved, respectively. And 296 trials were finally incorporated into the analysis.ResultsThe scientometric analysis showed that the study of immunotherapies in cervical cancer developed fast in recent years. Most publications were from the United States, followed by China. Seven of the top 10 co-cited references belong to clinical trials, and five of them were published in recent five years. There are lots of clinical trials us specific treatment patterns, some of which have represented excellent effects.ConclusionsBoth the scientometric analysis of the 1,255 publications and the analysis of clinical trials showed that the field of immunotherapies in cervical cancer developed so fast in recent years. It was found that a lot of clinical trials using various immunotherapies (mainly vaccine therapy, adoptive cell therapy, immune checkpoint blockade, and antibody-drug conjugate) for advanced cervical cancer are currently ongoing or have represented considerable effect. Centered in immunotherapies, immune checkpoint blockades have represented great efficacy and huge potential, especially combined with other therapies such as chemotherapy, targeted therapy, and other immunotherapies.

show abstract

PD‐L1/TIGIT bispecific antibody showed survival advantage in animal model

Cited by 11 publications

References 10 publications

Anti-TIGIT therapies for solid tumors: a systematic review

Anti-TIGIT therapies for solid tumors: a systematic review

Bispecific antibodies targeting immunomodulatory checkpoints for cancer therapy

Immunotherapy in cervical cancer: From the view of scientometric analysis and clinical trials

Contact Info

Product

Resources

About